Rezultati pretraživanja
  1. 31. sij

    Translation: PTC Therapeutics announced at the 38th annual J.P. Morgan Healthcare 2020 conference, the continuation of PTC-FA gene therapy for which should lead to clinical trials in the 3rd quarter of 2020

  2. 30. sij

    💊PTC Therapeutics a annoncé lors de la 38ème conférence annuelle J.P. Morgan Healthcare 2020 la poursuite de la thérapie génique PTC-FA pour l' de qui devrait déboucher sur des essais cliniques au 3ème trimestre 2020

  3. 30. sij
  4. In the JANUARY ISSUE: Predictors of loss of ambulation in 's

  5. 28. sij

    . a annoncé l'attribution d'une subvention de 1 million $ pour faire avancer l'essai clinique de phase 2 d' sur une thérapie de remplacement génétique pour l' de

  6. 20. sij

    Our paper on longitudinal change in brain activation in Friedreich ataxia is now at We investigated changes in fMRI, associated with working memory performance, and grey matter volume over 24 months

  7. 14. sij

    Ensayo fase 1 Terapia potencial para la Aprobada para y fusionadas en Larimar Therapeutics avanzando en esta terapia de reemplazo de proteínas q apoya Gr.

  8. 13. sij
  9. 8. sij

    Excited to present my first doctoral thesis study, which has just been published! We investigated what different white matter modalities can tell us about the disease process in 🧠📚

    Prikaži ovu nit
  10. 5. pro 2019.
  11. 15. stu 2019.

    Looking forward to sharing my longitudinal analysis of brain white matter in - find me at Poster #35 (Natural History, Biomarkers and Endpoints) 🧠

  12. We are excited about these results of using omaveloxone The positive effect of omaveloxone in was first shown in our lab by Dr Rosella Abeti and published here

  13. 24. ruj 2019.

    Today is International Ataxia Awareness Day. Ataxia is a rare neurological disease impacting daily activities such as walking and talking. Through my research, I hope to contribute to better outcomes for individuals with .

  14. 17. lip 2019.

    is also a good candidate for with more studies to do on the best way to deliver the to by systemic injection or combined injection - ongoing progress reported by Massimo Pandolfo at the annual meeting

  15. 11. lip 2019.

    My supervisor will be presenting my multi-modal longitudinal analysis of white matter in at today's poster session (W220). This work is part of the IMAGE-FRDA Study, based at and .

  16. ❓J’interroge le sur le 2018-2022 et la prise en compte de l’ataraxie de et la maladie de . 👇

  17. 23. ožu 2019.

    Kyle Bryant is a rare disease advocate and the founder/director of for the ’s Ataxia Research Alliance . Kyle and his team produce family friendly bike rides to empower those with Friedreich’s Ataxia @ataxiaandme

  18. In the 👉🏻 Our member Minoryx Therapeutics receives approval from to initiate phase 2 study in 's Ataxia

  19. 28. velj 2019.
  20. 27. velj 2019.

    🗞️ recibe la aprobación de la Agencia Reguladora Española para iniciar el estudio de fase 2 en la ataxia de , que en España afecta a unas 2.000 personas ➡️

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.